Issue 4, 2025

Synthesis and preclinical evaluation of novel l-cystine-based polyamide nanocapsules loaded with a fixed-dose combination of thymoquinone and doxorubicin for targeted pulmonary anticancer drug delivery

Abstract

Innovative synthetic biodegradable polymers containing amino acid moieties are used as pulmonary anticancer drug delivery systems to efficiently administer drugs in a controlled manner while also altering the physical and chemical characteristics of therapeutic molecules and the way they are delivered to the lungs. In this study, the aim was to prepare a new polyamide based on L-cystine amino acid loaded with a combination of thymoquinone (TQ) and doxorubicin (DOX) nanocapsules (TQ-DOX/Cys-Py/PA NCs) to be delivered directly to the lungs. TQ-DOX/Cys-Py/PA NCs were created using a single-step interfacial polycondensation method. The aerodynamic performance assessment shows that the prepared TQ-DOX/Cys-Py/PA NCs were able to deliver 98.7% and 97.1% of the TQ and DOX nominated dose, respectively. TQ and DOX with emitted doses of 2008.2 and 110.2 μg can reach the lower parts of the respiratory system and have an aerodynamic particle size between 1 and 5 μm, which revealed that the optimum formulation would produce a small particle size (19.89 nm) with high entrapment efficiency (TQ: 85.4%, DOX: 99.49%) and loading efficiency (TQ: 52.2%, DOX: 15.03). The targeted release of TQ and DOX in 0.1 M GSH-containing buffer solution demonstrated a faster onset of action, with 50% released within the first 2 hours. In vivo studies were conducted to demonstrate the efficacy of TQ-DOX/Cys-Py/PA NCs in enabling targeted drug delivery to the lungs for the treatment of lung cancer. The results demonstrate exceptional lung targeting and sustained lung retention for at least 24 hours. Furthermore, the toxicity of the TQ-DOX/Cys-Py/PA NCs was assessed by quantifying the protein carbonyl content. The results showed that the TQ-DOX/Cys-Py/PA NCs exhibited reduced toxicity to the heart, liver, and kidney compared to free DOX and DOX/Cys-Py/PA NCs.

Graphical abstract: Synthesis and preclinical evaluation of novel l-cystine-based polyamide nanocapsules loaded with a fixed-dose combination of thymoquinone and doxorubicin for targeted pulmonary anticancer drug delivery

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
26 Sep 2024
Accepted
20 Jan 2025
First published
27 Jan 2025
This article is Open Access
Creative Commons BY license

Mater. Adv., 2025,6, 1497-1512

Synthesis and preclinical evaluation of novel L-cystine-based polyamide nanocapsules loaded with a fixed-dose combination of thymoquinone and doxorubicin for targeted pulmonary anticancer drug delivery

H. F. Banat, D. K. Ali, Q. Jarrar, E. Alomary and E. Z. Dahmash, Mater. Adv., 2025, 6, 1497 DOI: 10.1039/D4MA00972J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements